Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... by McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ

Connect to this object online.

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data by Espada G, Pardeo M, Chaitow J, Brown D, Allen R, Zulian F, Zuber Z, Wulffraat N, Joos R, Dolezalova P, Burgos-Vargas R, Woo P, Schneider R, Ruperto N, Brunner H, De Benedetti F, Flato B, Gerloni V, Horneff G, Wright S, Kenwright A, Lovell D, Martini A

Connect to this object online.